Home > Healthcare > Pharmaceuticals > Finished Drug Form > Oxycodone Drugs Market

Oxycodone Drugs Market Size

  • Report ID: GMI9228
  • Published Date: Apr 2024
  • Report Format: PDF

Oxycodone Drugs Market Size

Oxycodone Drugs Market size was valued at USD 5.4 billion in 2023 and is expected to grow at a CAGR of 5.7% between 2024 and 2032, driven by factors such as the rise in incidence of chronic pain diseases such as cancer, neuropathic disease, musculoskeletal disorders, and various others.


Also, the increase in the number of surgical procedures increases the demand for oxycodone drugs to manage postoperative pain, thereby driving market growth. For instance, according to an article published in National Library of Medicine in September 2021, it has been reported that, globally, over 310 million major surgeries are performed each year with around 40 to 50 million in U.S. and 20 million in Europe. It is estimated that up to 15% have serious postoperative morbidity, and 5–15% readmitted within 30 days. Thus, the rapid increase in the number of surgical procedures conducted globally, have increase the demand for oxycodone drugs to treat post-operative pain, thereby propelling the market growth.

Oxycodone medication is prescribed for alleviating intense pain that necessitates opioid therapy, particularly when alternative pain relief options have proven ineffective or are unsuitable. Classified as a narcotic analgesic, oxycodone operates on the central nervous system to mitigate pain. It is accessible in various forms such as capsules, tablets, and liquid, and is offered in diverse potencies.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Oxycodone drugs industry size was USD 5.4 billion in 2023 and is projected to showcase 5.7% CAGR from 2024 to 2032, owing to the rise in incidence of chronic pain diseases like cancer, neuropathic disease, and musculoskeletal disorders.

The long-acting oxycodone segment in the market reached USD 3.4 billion in 2023 and is estimated to grow at substantial CAGR between 2024 and 2032, due to their convenience of less frequent dosing.

North America oxycodone drugs industry accumulated 42.7% revenue share in 2023 and is predicted to grow at notable rate between 2024 and 2032, owing to the increase in incidence of cancer and the rising trend of drug prescription to manage cancer-related pain.

Alvogen, Ani Pharmaceuticals, Inc., Daiichi Sankyo Company Ltd., Endo Pharmaceuticals, Mallinckrodt Pharmaceuticals, Mylan N.V., Protega Pharmaceuticals LLC, Purdue Pharma LP, Quagen Pharma, and Teva Pharmaceuticals, Inc.

Oxycodone Drugs Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 268
  • Countries covered: 22
  • Pages: 162
 Download Free Sample